186 related articles for article (PubMed ID: 29936069)
1. SPX-101 is stable in and retains function after exposure to cystic fibrosis sputum.
Sesma JI; Wu B; Stuhlmiller TJ; Scott DW
J Cyst Fibros; 2019 Mar; 18(2):244-250. PubMed ID: 29936069
[TBL] [Abstract][Full Text] [Related]
2. Identification of the SPLUNC1 ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airway epithelial cultures.
Hobbs CA; Blanchard MG; Alijevic O; Tan CD; Kellenberger S; Bencharit S; Cao R; Kesimer M; Walton WG; Henderson AG; Redinbo MR; Stutts MJ; Tarran R
Am J Physiol Lung Cell Mol Physiol; 2013 Dec; 305(12):L990-L1001. PubMed ID: 24124190
[TBL] [Abstract][Full Text] [Related]
3. SPX-101 Is a Novel Epithelial Sodium Channel-targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport.
Scott DW; Walker MP; Sesma J; Wu B; Stuhlmiller TJ; Sabater JR; Abraham WM; Crowder TM; Christensen DJ; Tarran R
Am J Respir Crit Care Med; 2017 Sep; 196(6):734-744. PubMed ID: 28481660
[TBL] [Abstract][Full Text] [Related]
4. SPLUNC1 degradation by the cystic fibrosis mucosal environment drives airway surface liquid dehydration.
Webster MJ; Reidel B; Tan CD; Ghosh A; Alexis NE; Donaldson SH; Kesimer M; Ribeiro CMP; Tarran R
Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30190268
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a SPLUNC1-derived peptide for the treatment of cystic fibrosis lung disease.
Terryah ST; Fellner RC; Ahmad S; Moore PJ; Reidel B; Sesma JI; Kim CS; Garland AL; Scott DW; Sabater JR; Carpenter J; Randell SH; Kesimer M; Abraham WM; Arendshorst WJ; Tarran R
Am J Physiol Lung Cell Mol Physiol; 2018 Jan; 314(1):L192-L205. PubMed ID: 28982737
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways.
Garland AL; Walton WG; Coakley RD; Tan CD; Gilmore RC; Hobbs CA; Tripathy A; Clunes LA; Bencharit S; Stutts MJ; Betts L; Redinbo MR; Tarran R
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):15973-8. PubMed ID: 24043776
[TBL] [Abstract][Full Text] [Related]
7. SPLUNC1 as a biomarker of pulmonary exacerbations in children with cystic fibrosis.
Ben-Meir E; Perrem L; Shaw M; Ratjen F; Grasemann H
J Cyst Fibros; 2024 Mar; 23(2):288-292. PubMed ID: 38413298
[TBL] [Abstract][Full Text] [Related]
8. Differential epithelial expression of the putative innate immune molecule SPLUNC1 in cystic fibrosis.
Bingle L; Barnes FA; Cross SS; Rassl D; Wallace WA; Campos MA; Bingle CD
Respir Res; 2007 Nov; 8(1):79. PubMed ID: 17988392
[TBL] [Abstract][Full Text] [Related]
9. First clinical trials of novel ENaC targeting therapy, SPX-101, in healthy volunteers and adults with cystic fibrosis.
Couroux P; Farias P; Rizvi L; Griffin K; Hudson C; Crowder T; Tarran R; Tullis E
Pulm Pharmacol Ther; 2019 Oct; 58():101819. PubMed ID: 31302339
[TBL] [Abstract][Full Text] [Related]
10. SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage.
Garcia-Caballero A; Rasmussen JE; Gaillard E; Watson MJ; Olsen JC; Donaldson SH; Stutts MJ; Tarran R
Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11412-7. PubMed ID: 19541605
[TBL] [Abstract][Full Text] [Related]
11. The SPLUNC1-βENaC complex prevents Burkholderia cenocepacia invasion in normal airway epithelia.
Ahmad S; Kim CSK; Tarran R
Respir Res; 2020 Jul; 21(1):190. PubMed ID: 32680508
[TBL] [Abstract][Full Text] [Related]
12. SPLUNC1 is an allosteric modulator of the epithelial sodium channel.
Kim CS; Ahmad S; Wu T; Walton WG; Redinbo MR; Tarran R
FASEB J; 2018 May; 32(5):2478-2491. PubMed ID: 29295861
[TBL] [Abstract][Full Text] [Related]
13. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.
Moore PJ; Tarran R
Expert Opin Ther Targets; 2018 Aug; 22(8):687-701. PubMed ID: 30028216
[TBL] [Abstract][Full Text] [Related]
14. Thickness of the airway surface liquid layer in the lung is affected in cystic fibrosis by compromised synergistic regulation of the ENaC ion channel.
Olivença DV; Fonseca LL; Voit EO; Pinto FR
J R Soc Interface; 2019 Aug; 16(157):20190187. PubMed ID: 31455163
[TBL] [Abstract][Full Text] [Related]
15. Identification of SPLUNC1's ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airways.
Hobbs CA; Blanchard MG; Kellenberger S; Bencharit S; Cao R; Kesimer M; Walton WG; Redinbo MR; Stutts MJ; Tarran R
FASEB J; 2012 Oct; 26(10):4348-59. PubMed ID: 22798424
[TBL] [Abstract][Full Text] [Related]
16. Effect of neutrophil elastase and its inhibitor EPI-hNE4 on transepithelial sodium transport across normal and cystic fibrosis human nasal epithelial cells.
Prulière-Escabasse V; Clerici C; Vuagniaux G; Coste A; Escudier E; Planès C
Respir Res; 2010 Oct; 11(1):141. PubMed ID: 20932306
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Protease-Epithelial Sodium Channel Signaling Improves Mucociliary Function in Cystic Fibrosis Airways.
Reihill JA; Walker B; Hamilton RA; Ferguson TE; Elborn JS; Stutts MJ; Harvey BJ; Saint-Criq V; Hendrick SM; Martin SL
Am J Respir Crit Care Med; 2016 Sep; 194(6):701-10. PubMed ID: 27014936
[TBL] [Abstract][Full Text] [Related]
18. New generation ENaC inhibitors detach cystic fibrosis airway mucus bundles via sodium/hydrogen exchanger inhibition.
Giorgetti M; Klymiuk N; Bähr A; Hemmerling M; Jinton L; Tarran R; Malmgren A; Åstrand A; Hansson GC; Ermund A
Eur J Pharmacol; 2021 Aug; 904():174123. PubMed ID: 33974881
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fibrosis bronchial epithelial cells.
Mroz MS; Harvey BJ
Steroids; 2019 Nov; 151():108461. PubMed ID: 31344409
[TBL] [Abstract][Full Text] [Related]
20. ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art.
Althaus M
Curr Mol Pharmacol; 2013 Mar; 6(1):3-12. PubMed ID: 23547930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
